이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention

2014년 6월 13일 업데이트: Peter Weiden, University of Illinois at Chicago
This is a randomized pilot study of an intervention based on principles of Cognitive Behavioral Therapy (CBT). This intervention is the Health Dialogue Intervention (HDI) and will be compared to a traditional medical model of psychoeducation known as Team Solutions (TS) for first-episode schizophrenia patients. Outcomes include the acceptance of HDI and TS, compare adherence attitudes at the end of the treatment intervention, and to compare the time until the first episode of nonadherence.

연구 개요

상세 설명

Overview: Many people recovering from first-episode schizophrenia typically respond very well to their initial course of antipsychotic medications; however, studies indicate that nonadherence rates soar as high as 90% in the first year and do not improve over time. To date, there is no effective psychosocial intervention that improves adherence or reduces the adverse consequences of nonadherence after it occurs. Thus, it is imperative to develop a new intervention to improve medication adherence and improve clinical outcomes in patients recovering from first-episode schizophrenia.

This study is to pilot an intervention specifically suited for patients with first-episode schizophrenia based on the principles of Cognitive Behavioral Therapy (CBT). This is to focus on adherence from the perspective of the patient.

Methods: This study compares the effectiveness of a standard psychoeducation program [Team Solutions (TS)] to a CBT approach known as the Health Dialogue Intervention (HDI). Consenting patients will receive a 4 week stabilization assessment period and then be randomized to a prospective, random-assignment study comparing the effectiveness of TS to HDI to improve medication adherence of patients recovering from first-episode schizophrenia.

연구 유형

중재적

등록 (실제)

34

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Illinois
      • Chicago, Illinois, 미국, 60612
        • University of Illinois at Chicago

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

16년 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

There is a 2 step inclusion/exclusion criteria, the first being for assessing overall eligibility to enter the study, and then, for continued outpatient treatment for schizophrenia, schizophreniform disorder, or schizoaffective disorder.

Inclusion criteria for entry into the Evaluation Phase:

  1. Between 16-45 years of age
  2. A provisional clinical diagnosis of schizophreniform disorder, schizophrenia, or schizoaffective disorder in last 6 months
  3. Discharge from inpatient unit for treatment of psychotic symptoms must have occurred in the last 6 months, or, if never hospitalized, initial treatment started in the last 6 months
  4. Able to fully participate in the informed consent process
  5. The patient is judged to be an appropriate candidate for ongoing outpatient follow-up at the First-episode Treatment Program at the Psychotic Disorders Program at UIC

Exclusion criteria for the Evaluation Phase:

  1. Unable to understand informed consent process
  2. A history of nonresponse to prior antipsychotic trials such that long-term inpatient treatment or clozapine will be recommended
  3. Prior treatment with clozapine
  4. Discharge from inpatient treatment for psychotic symptoms, initial treatment, or provisional diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform occurred more than 6 months from enrollment into the evaluation phase
  5. Pregnancy or stated goal to become pregnant
  6. Will not be living close enough to the medical center to return for follow-up visits or assessments
  7. History of geographic instability such that it is judged unlikely that patient will reside in the area
  8. Currently under arrest for a felony, or an arrest is deemed likely in the near future
  9. Currently receiving medication over objection by court order
  10. Currently receiving treatment in another research protocol

Inclusion Criteria for the Treatment Intervention Phase:

  1. Willingness to transition to receive evaluation and future pharmacologic treatment at the Psychotic Disorders Program at UIC
  2. Has capacity to understand the risks and benefits of participating in a randomized psychosocial trial
  3. Willingness to sign informed consent to go into the Treatment Intervention Phase
  4. Is able to complete a post-test for understanding the nature of the study and what it entails, and the potential risks and benefits of study participation
  5. Is willing to have therapy sessions recorded for fidelity assessments
  6. Is willing to receive follow-up independent assessments of adherence status, including separate interviews with trained independent raters, and our contacting the outpatient pharmacy for pharmacy refill records

Exclusion criteria for Treatment Intervention Phase:

  1. Diagnosis or inpatient treatment for psychotic symptoms occurred more than 6 months from date of enrollment into evaluation phase
  2. Acutely psychotic individuals may not participate because therapy will not benefit if symptoms are too severe
  3. Has dropped out of the treatment program and cannot be located for follow-up appointments
  4. Stated refusal to come for to at least one clinical evaluation appointment at the PDP, or has been a "no show" for at least three consecutive appointments
  5. Judged to be at significant and imminent risk of harm to self or others*
  6. Ongoing active substance or alcohol use that is not controlled during the Evaluation Phase, along with refusal of referral to a "dual diagnosis" treatment program for substance abuse problems
  7. Remains enrolled in another research protocol at UIC*
  8. Unwilling to consider any additional psychotherapeutic intervention above and beyond coming in to the service for medication management appointment
  9. Baseline PANSS total score ≥ 90, or has a individual PANSS item of conceptual disorganization (item P2), excitement (P4), or hostility (P7) that is ≥ 5 (moderately severe)*
  10. Judged to require additional concrete case management services to support medication adherence*
  11. Receives antipsychotics under coercive conditions (e.g. inpatient or outpatient commitment)*

Note: The exclusion criteria (*) may be present during some parts of the Evaluation Phase and would need to be resolved within the 4 week time period permitted for the Evaluation Phase prior to the Treatment Intervention Phase of study entry.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: CBT
UK-based intervention
Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
1. Acceptance of therapeutic intervention as measured by number of sessions attended. 2. Difference in adherence behavior as measured by duration of antipsychotic treatment during follow up (ASV). 3. Differences in adherence attitudes (ROMI).
기간: Completion of Study
Completion of Study

2차 결과 측정

결과 측정
기간
1. Compare the course of symptoms and relapse of patients in HDI to those in the TS.
기간: Completion of Study
Completion of Study

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Peter J. Weiden, M.D., University of Illinois at Chicago

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2009년 11월 1일

기본 완료 (실제)

2012년 12월 1일

연구 완료 (실제)

2013년 3월 1일

연구 등록 날짜

최초 제출

2009년 9월 18일

QC 기준을 충족하는 최초 제출

2009년 9월 18일

처음 게시됨 (추정)

2009년 9월 21일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2014년 6월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2014년 6월 13일

마지막으로 확인됨

2014년 6월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

Cognitive Behavioral Therapy에 대한 임상 시험

3
구독하다